WaveMan
WaveMan · Company
RZLT · Rezolute, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RZLT Rezolute (RZLT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001509261
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
99
13F, latest reported quarter

Rezolute insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Rezolute, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Evans Daron
CFO
BUY
2026-03-31 SECtraded 2026-03-30
10,000
$28.5K
+23.2%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Dec 15, 2025.
  • +42.2% median (+52.3% mean) 90-day return after 13 previous buys.
  • The trade is 2.4% of the 414,462 shares held after it.
  • No other insider bought within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Evans Daron bought about $28.5K of RZLT on Mar 30, 2026; 99 funds added in the latest 13F quarter.
Hogenhuis Wladimir
Director
BUY
2025-12-17 SECtraded 2025-12-16
5,650
$9.5K
+108.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Mar 31, 2025.
  • -10.9% median (+0.1% mean) 90-day return after 6 previous buys.
  • The trade is 4.7% of the 119,675 shares held after it.
  • 4 other insiders bought within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hogenhuis Wladimir bought about $9.5K of RZLT on Dec 16, 2025; 4 other insiders bought within 30 days and 99 funds added in the latest 13F quarter.
ROBERTS BRIAN KENNETH
Chief Medical Officer
BUY
2025-12-17 SECtraded 2025-12-16
28,000
$47.6K
+108.4%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 buys), the last on Jun 25, 2025.
  • +49.5% median (+64.0% mean) 90-day return after 14 previous buys.
  • The trade is 9.1% of the 308,352 shares held after it.
  • 4 other insiders bought within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer ROBERTS BRIAN KENNETH bought about $47.6K of RZLT on Dec 16, 2025; 4 other insiders bought within 30 days and 99 funds added in the latest 13F quarter.
Evans Daron
CFO
BUY
2025-12-15 SEC
40,000
$70.8K
+90.8%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Dec 9, 2025.
  • +37.2% median (+52.3% mean) 90-day return after 12 previous buys.
  • The trade is 9.6% of the 415,900 shares held after it.
  • 4 other insiders bought within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Evans Daron bought about $70.8K of RZLT on Dec 15, 2025; 4 other insiders bought within 30 days and 99 funds added in the latest 13F quarter.
Evans Daron
CFO
BUY
2025-12-15 SEC
2,500
$4.5K
+90.8%
Context
  • 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Dec 9, 2025.
  • +37.2% median (+52.3% mean) 90-day return after 12 previous buys.
  • The trade is 35.7% of the 7,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • 99 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Evans Daron bought about $4.5K of RZLT on Dec 15, 2025; 4 other insiders bought within 30 days and 99 funds added in the latest 13F quarter.
57 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 52 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
99 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
27.5% of the float short (float per yahoo 2026-10-26) · 8.9 days to cover · settled 2026-09-30
more than 90% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RZLT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-57.3%12M
-84%-49%-14%+21%2025-102025-122026-022026-042026-062026-08 2025-12-15 · Evans Daron bought $70.8K2025-12-09 · Evans Daron bought $53.2K2025-12-15 · Elam Nevan C bought $50.9K2025-12-16 · ROBERTS BRIAN KENNETH bought $47.6K2026-03-30 · Evans Daron bought $28.5K2025-12-15 · Karnawat Sunil Ratilal bought $19.4K2025-12-16 · Hogenhuis Wladimir bought $9.5K2025-12-15 · Evans Daron bought $4.5K2025-12-15 · Karnawat Sunil Ratilal bought $160
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RZLT: institutional holders (13F)

13F holdings, latest reported quarter
FEDERATED HERMES, INC.
12,990,659 sh
$67.6M
RA CAPITAL MANAGEMENT, L.P.
9,445,039 sh
$49.1M
BlackRock, Inc.
7,718,291 sh
$40.1M
Opaleye Management Inc.
6,300,000 sh
$32.8M
Balyasny Asset Management L.P.
4,662,039 sh
$24.2M

Congress trades in RZLT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RZLT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

RZLT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Federated Hermes Kaufmann Small Cap Fund
$25.2M position · as of 2026-07-31
0.9%
AlphaCentric Life Sciences and Healthcare Fund
$375.7K position · as of 2026-06-30
0.8%
Virtus Biotech Clinical Trials Etf
$366.8K position · as of 2026-07-31
0.8%
Federated Hermes Kaufmann Fund II
$862.2K position · as of 2026-06-30
0.8%
Federated Hermes Kaufmann Fund
$35.3M position · as of 2026-07-31
0.7%
Janus Henderson Small Cap Growth Alpha ETF
$1.5M position · as of 2026-07-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.7M
$4.1M
$2.5M
+163%
n/a
2024
$2.9M
$2.1M
$1.6M
+125%
n/a
2023
$1.2M
$5.0M
$601.0K
+117%
n/a
2022
$973.6K
-$2.0M
$738.9K
-86%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 99 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RZLT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$64.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.14x
LongTermDebt as filed 2022-03-31 (51 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-4.52x
TTM operating cash flow over LongTermDebt as filed 2022-03-31 (51 months older than the period end) (includes the current portion)
Return on equity
-59.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-62.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$376.5M
market value at close 2026-10-23 on 2026-09-21 shares, plus LongTermDebt as filed 2022-03-31 (51 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-17.4%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Operating income-$83.0M-$79.9M-$70.4M-$56.0M
Net income-$77.6M-$74.4M-$68.5M-$51.8M
EPS (diluted)-0.75-0.98-1.33-1.01
Operating cash flow-$64.6M-$69.1M-$57.4M-$44.5M
Cash$10.6M$94.1M$70.4M$16.0M
Buybacksn/an/a$3.0Kn/a
SEC XBRL, fiscal years, as known on 2026-10-28

RZLT Stock Sonar score 4/7 axes

Find similar shapesCompare

RZLT ranks highest on institutional and government (52nd percentile) and profitability (44th), and lowest on risk and compliance (6th), among Pharma & Biotech peers.

Profitability
44
Inputs
  • Return on equity-59.0% · 49 pct, sector of 545
  • Return on assets-53.8% · 42 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-62.6% · 41 pct, sector of 576
Financial health
40
Inputs
  • Debt to equity0.14x · 50 pct, sector of 352
  • Cash flow to debt-4.52x · 31 pct, sector of 371
Institutional and government
52
Inputs
  • Funds adding, latest quarter99 · 68 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$180K · 37 pct, sector of 133
Risk and compliance
6
Inputs
  • Short interest, % of float+27.5% · 6 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies